IELSG30 2期试验:原发性睾丸弥漫性大B细胞淋巴瘤的静脉与鞘内中枢神经系统预防
IELSG30 2期研究评估强化鞘内和静脉中枢神经系统预防在I/II期原发性睾丸弥漫性大B细胞淋巴瘤中的可行性和活性。54例患者接受R-CHOP方案后2周期大剂量甲氨蝶呤静脉注射及鞘内脂质体阿糖胞苷,并推荐对侧睾丸放疗。中位随访6年无中枢神经系统复发,5年无进展生存率和总生存率分别为91%和92%,晚期结外复发为主要失败模式。
要点
- 强化鞘内和静脉中枢神经系统预防在原发性睾丸弥漫性大B细胞淋巴瘤中可行且有效预防中枢神经系统复发。
- 中位随访6年无中枢神经系统复发,5年无进展生存率91%,总生存率92%。
- 晚期复发(主要位于结外)是最相关的失败模式,4例复发发生在治疗后6年以上。
核心结论
- 强化预防在预防中枢神经系统复发方面可行且有效,晚期复发(主要位于结外)是最相关的失败模式。
研究设计与样本
- IELSG30 2期研究纳入54例未经治疗的I期(n=32)或II期(n=22)原发性睾丸弥漫性大B细胞淋巴瘤患者,中位年龄66岁。
主要发现
- 53例接受至少3剂鞘内阿糖胞苷,48例接受至少1剂静脉甲氨蝶呤,50例接受预防性放疗,未发生意外毒性。
- 中位随访6年,无中枢神经系统复发;7例进展,8例死亡,5年无进展生存率91%(95%CI 79-96),总生存率92%(95%CI 81-97)。
- 6例记录到结外复发(其中2例无淋巴结受累),4例复发发生在治疗后6年以上。
- 死亡原因:淋巴瘤4例,第二原发恶性肿瘤1例,脑血管病1例,不明2例。
关键数值与推荐
- 患者接受6周期R-CHOP方案(利妥昔单抗、环磷酰胺、多柔比星、长春新碱、泼尼松,每21天),随后2周期静脉大剂量甲氨蝶呤(1.5 g/m2)。
- 鞘内脂质体阿糖胞苷在21天R-CHOP方案的第2至第5周期的第0天给药。
- 推荐对侧睾丸放疗(25-30 Gy)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Primary testicular diffuse large B-cell lymphoma (PTL) is characterized by high risk of contralateral testis and central nervous system (CNS) relapse. Chemoimmunotherapy with intrathecal (IT) CNS prophylaxis and contralateral testis irradiation eliminates contralateral recurrences and reduces CNS relapses. The IELSG30 phase 2 study investigated feasibility and activity of an intensified IT and IV CNS prophylaxis. Patients with stage I/II PTL who had not received treatment received 2 cycles of IV high-dose methotrexate (MTX) (1.5 g/m2) after 6 cycles of the R-CHOP regimen (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, every 21 days). IT liposomal cytarabine was administered on day 0 of cycles 2 to 5 of 21-day R-CHOP regimen. Contralateral testis radiotherapy (25-30 Gy) was recommended. Fifty-four patients (median age: 66 years) with stage I (n = 32) or II (n = 22) disease were treated with R-CHOP, 53 received at least 3 doses of IT cytarabine, 48 received at least 1 dose of IV MTX, and 50 received prophylactic radiotherapy. No unexpected toxicity occurred. At a median follow-up of 6 years, there was no CNS relapse; 7 patients progressed, and 8 died, with 5-year progression-free and overall survival rates of 91% (95% confidence interval [CI], 79-96) and 92% (95% CI, 81-97), respectively. Extranodal recurrence was documented in 6 patients (in 2 without nodal involvement). In 4 cases, the relapse occurred >6 years after treatment. Causes of death were lymphoma (n = 4), second primary malignancy (n = 1), cerebral vasculopathy (n = 1), unknown (n = 2). Intensive prophylaxis was feasible and effective in preventing CNS relapses. Late relapses, mainly at extranodal sites, represented the most relevant pattern of failure. This trial was registered at www.clinicaltrials.gov as #NCT00945724.
引用
- Conconi A, Chiappella A, Ferreri AJM, et al. IELSG30 phase 2 trial: intravenous and intrathecal CNS prophylaxis in primary testicular diffuse large B-cell lymphoma. Blood Adv. 2024. PMID: 38181782. doi:10.1182/bloodadvances.2023011251
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。